Based upon the clinical behavior of three patients, we suggest that the combination of low-dose Ara-C and all-trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1-mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature / Forghieri, F., Bigliardi, S., Quadrelli, C., Morselli, M., Potenza, L., Paolini, A., Colaci, E., Barozzi, P., Zucchini, P., Riva, G., Vallerini, D., Lagreca, I., Marasca, R., Narni, F., Venditti, A., Martelli, M.P., Falini, B., Lo Coco, F., Amadori, S., Luppi, M.. - In: CLINICAL CASE REPORTS. - ISSN 2050-0904. - 4:12(2016), pp. 1138-1146-1146. [10.1002/ccr3.723]
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature
FORGHIERI, Fabio;BIGLIARDI, Sara;QUADRELLI, Chiara;MORSELLI, Monica;POTENZA, Leonardo;PAOLINI, Ambra;COLACI, ELISABETTA;BAROZZI, Patrizia;ZUCCHINI, Patrizia;RIVA, Giovanni;VALLERINI, Daniela;LAGRECA, IVANA;MARASCA, Roberto;NARNI, Franco;LUPPI, Mario
2016
Abstract
Based upon the clinical behavior of three patients, we suggest that the combination of low-dose Ara-C and all-trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1-mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Clin Case Report_Forghieri et al_2016.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
81.08 kB
Formato
Adobe PDF
|
81.08 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
